Actions of tacrine and galanthamine on histamine-N-methyltransferase

O. D. Taraschenko, W. G. Barnes, K. Herrick-Davis, Y. Yokoyama, D. L. Boyd, Lindsay B. Hough

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Histamine-synthesizing neurons in the brain may play an important role in cognition, and a histaminergic deficit has been found in Alzheimer's disease (AD). The AD medication tacrine was previously shown to inhibit some forms of rodent histamine-N-methyltransferase (HNMT), but the effects of AD drugs have not been investigated on human HNMT activity. Presently, the effects of tacrine and galanthamine (another AD medication) were studied on the activity of several forms of human and rat HNMT. Tacrine (0.01-10 μM) inhibited both human and rat HNMT activity in a concentration-dependent manner, but was less potent on both human embryonic kidney and recombinant human brain HNMT than on rat kidney HNMT (IC50 values were 0.46 and 0.70 μM vs. 0.29 μM, respectively). Galanthamine (up to 10 μM) did not influence the activity of rat kidney or human HNMT. Tacrine, but not galanthamine, may achieve brain levels sufficient to influence histamine metabolism in some patients treated for AD.

Original languageEnglish (US)
Pages (from-to)161-165
Number of pages5
JournalMethods and Findings in Experimental and Clinical Pharmacology
Volume27
Issue number3
DOIs
StatePublished - Apr 1 2005

Fingerprint

Histamine N-Methyltransferase
Galantamine
Tacrine
Alzheimer Disease
Kidney
Histamine
Brain
Cognition
Inhibitory Concentration 50
Rodentia
Neurons

Keywords

  • Alzheimer's disease
  • Galanthamine
  • Histamine-N-methyltransferase
  • Tacrine

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Actions of tacrine and galanthamine on histamine-N-methyltransferase. / Taraschenko, O. D.; Barnes, W. G.; Herrick-Davis, K.; Yokoyama, Y.; Boyd, D. L.; Hough, Lindsay B.

In: Methods and Findings in Experimental and Clinical Pharmacology, Vol. 27, No. 3, 01.04.2005, p. 161-165.

Research output: Contribution to journalArticle

Taraschenko, O. D. ; Barnes, W. G. ; Herrick-Davis, K. ; Yokoyama, Y. ; Boyd, D. L. ; Hough, Lindsay B. / Actions of tacrine and galanthamine on histamine-N-methyltransferase. In: Methods and Findings in Experimental and Clinical Pharmacology. 2005 ; Vol. 27, No. 3. pp. 161-165.
@article{1059ba9cad4040e2a1a850f7c7cb7c57,
title = "Actions of tacrine and galanthamine on histamine-N-methyltransferase",
abstract = "Histamine-synthesizing neurons in the brain may play an important role in cognition, and a histaminergic deficit has been found in Alzheimer's disease (AD). The AD medication tacrine was previously shown to inhibit some forms of rodent histamine-N-methyltransferase (HNMT), but the effects of AD drugs have not been investigated on human HNMT activity. Presently, the effects of tacrine and galanthamine (another AD medication) were studied on the activity of several forms of human and rat HNMT. Tacrine (0.01-10 μM) inhibited both human and rat HNMT activity in a concentration-dependent manner, but was less potent on both human embryonic kidney and recombinant human brain HNMT than on rat kidney HNMT (IC50 values were 0.46 and 0.70 μM vs. 0.29 μM, respectively). Galanthamine (up to 10 μM) did not influence the activity of rat kidney or human HNMT. Tacrine, but not galanthamine, may achieve brain levels sufficient to influence histamine metabolism in some patients treated for AD.",
keywords = "Alzheimer's disease, Galanthamine, Histamine-N-methyltransferase, Tacrine",
author = "Taraschenko, {O. D.} and Barnes, {W. G.} and K. Herrick-Davis and Y. Yokoyama and Boyd, {D. L.} and Hough, {Lindsay B.}",
year = "2005",
month = "4",
day = "1",
doi = "10.1358/mf.2005.27.3.890872",
language = "English (US)",
volume = "27",
pages = "161--165",
journal = "Methods and Findings in Experimental and Clinical Pharmacology",
issn = "0379-0355",
publisher = "Prous Science",
number = "3",

}

TY - JOUR

T1 - Actions of tacrine and galanthamine on histamine-N-methyltransferase

AU - Taraschenko, O. D.

AU - Barnes, W. G.

AU - Herrick-Davis, K.

AU - Yokoyama, Y.

AU - Boyd, D. L.

AU - Hough, Lindsay B.

PY - 2005/4/1

Y1 - 2005/4/1

N2 - Histamine-synthesizing neurons in the brain may play an important role in cognition, and a histaminergic deficit has been found in Alzheimer's disease (AD). The AD medication tacrine was previously shown to inhibit some forms of rodent histamine-N-methyltransferase (HNMT), but the effects of AD drugs have not been investigated on human HNMT activity. Presently, the effects of tacrine and galanthamine (another AD medication) were studied on the activity of several forms of human and rat HNMT. Tacrine (0.01-10 μM) inhibited both human and rat HNMT activity in a concentration-dependent manner, but was less potent on both human embryonic kidney and recombinant human brain HNMT than on rat kidney HNMT (IC50 values were 0.46 and 0.70 μM vs. 0.29 μM, respectively). Galanthamine (up to 10 μM) did not influence the activity of rat kidney or human HNMT. Tacrine, but not galanthamine, may achieve brain levels sufficient to influence histamine metabolism in some patients treated for AD.

AB - Histamine-synthesizing neurons in the brain may play an important role in cognition, and a histaminergic deficit has been found in Alzheimer's disease (AD). The AD medication tacrine was previously shown to inhibit some forms of rodent histamine-N-methyltransferase (HNMT), but the effects of AD drugs have not been investigated on human HNMT activity. Presently, the effects of tacrine and galanthamine (another AD medication) were studied on the activity of several forms of human and rat HNMT. Tacrine (0.01-10 μM) inhibited both human and rat HNMT activity in a concentration-dependent manner, but was less potent on both human embryonic kidney and recombinant human brain HNMT than on rat kidney HNMT (IC50 values were 0.46 and 0.70 μM vs. 0.29 μM, respectively). Galanthamine (up to 10 μM) did not influence the activity of rat kidney or human HNMT. Tacrine, but not galanthamine, may achieve brain levels sufficient to influence histamine metabolism in some patients treated for AD.

KW - Alzheimer's disease

KW - Galanthamine

KW - Histamine-N-methyltransferase

KW - Tacrine

UR - http://www.scopus.com/inward/record.url?scp=17644418402&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=17644418402&partnerID=8YFLogxK

U2 - 10.1358/mf.2005.27.3.890872

DO - 10.1358/mf.2005.27.3.890872

M3 - Article

C2 - 15834447

AN - SCOPUS:17644418402

VL - 27

SP - 161

EP - 165

JO - Methods and Findings in Experimental and Clinical Pharmacology

JF - Methods and Findings in Experimental and Clinical Pharmacology

SN - 0379-0355

IS - 3

ER -